New obesity drug retatrutide shows significant weight loss and metabolic benefits in phase 3 trial
Միայն փաստեր

New obesity drug retatrutide shows significant weight loss and metabolic benefits in phase 3 trial

Ամփոփում

In a large double-blind study, the experimental drug retatrutide helped participants with obesity and type 2 diabetes lose up to 19% of body weight and improve blood-sugar control, though it is not yet approved.

A multinational phase-3 trial involving 2,047 adults with a body-mass index of 27 or higher and type 2 diabetes found that weekly injections of retatrutide produced notable weight loss and metabolic improvements. Participants receiving the highest dose (12 mg) lost an average of 18.8% of their body weight, compared with a 5.1% loss in the placebo group. Nearly half of those on the 12 mg dose shed at least 20% of their initial weight, and 31% lost at least a quarter of it.

The drug, which mimics the gut hormones GLP-1, GIP and glucagon, also helped 72% of treated participants achieve an HbA1c level of 6.5% or lower, versus 29% on placebo, and produced favorable changes in blood pressure, lipid profiles and inflammatory markers such as high-sensitivity C-reactive protein.

"Retatrutide demonstrated substantial reduction in body weight alongside glycaemic control and cardiometabolic risk factors, with a safety profile generally similar to other molecules with GLP-1 receptor agonist activity," the study authors said.

Gastrointestinal side effects were the most common adverse events, with diarrhoea reported in 27-34% of retatrutide recipients and nausea in 14-28%, compared with lower rates in the placebo group. Seven deaths occurred during the trial; investigators deemed them unrelated to the drug.

The findings, funded by Eli Lilly, were published in The Lancet and presented at the European Association for the Study of Diabetes meeting in Milan.

Աղբյուր

The Guardian

Շարունակեք կարդալ — անվճար

Ստեղծեք անվճար հաշիվ՝ նորություններին հետևելու համար։ Քարտ չի պահանջվում։